RESUMO
OBJECTIVE: Of study is improving the results of treatment of patients with pyo-necrotic complications of diabetic foot syndrome by including the method of negative pressure wound treatment in the complex treatment program in combination with using of the combined antibacterial drug Cifran ST and immunocorrective therapy. MATERIAL AND METHODS: The results of examination and treatment of 184 patients with pyo-necrotic complications of the neuropathic form of diabetic foot syndrome were analyzed. According to choice of treatment methods in the postoperative period all patients were divided into two groups. In 95 patients (group I), iodine-containing ointments based on polyethylene glycol were used for local treatment of purulent foot wounds and standard systemic antibacterial therapy was performed. In 89 patients (group II), negative pressure wound treatment (NPWT) was used to treat wounds in the postoperative period. In addition to standard parenteral antimicrobial therapy, these patients also received an oral combined antibacterial drug Cifran ST and immunocorrective cytokine therapy (Leukinferon). The analysis of the dynamics of the wound process was carried out based on the clinical picture and the results of cytological, bacteriological and immunological studies of the wound exudate. RESULTS: The presented strategy of complex treatment of pyo-necrotic complications of the neuropathic form of diabetic foot syndrome allowed group II patients to significantly reduce the degree of microbial contamination of wounds, to achieve a faster regression of the content of proinflammatory and inflammatory cytokines in the wound exudate, as well as to reduce the time of wound cleansing and the transition of the pyo-necrotic process to the reparative stage in comparison with group I patients. This allowed group II patients to reduce the time of plastic closure of the wound from 24.3±0.5 to 15.6±1.7 days, to avoid generalization of infection, death and high level amputation of the limb. At the same time, 11.6% of patients in group I had high level limb amputation due to generalization of infection. The mortality rate in group I was 5.3%. CONCLUSIONS: Adding of vacuum therapy of wounds, systemic antimicrobial therapy using the combined antibacterial drug Cifran ST and immunocorrective cytokine therapy in the complex treatment program for patients with neuropathic form of diabetic foot syndrome after radical surgical treatment of the pyo-necrotic lesion allows reducing the time of wound cleansing and the transition of the pyo-necrotic process to the reparative stage. On the other hand, this makes it possible for this category of patients to perform plastic closure of the wound at an earlier date, avoid generalization of infection and high level amputation of the limb.
Assuntos
Pé Diabético/terapia , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/uso terapêutico , Amputação Cirúrgica , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Ciprofloxacina/administração & dosagem , Ciprofloxacina/análogos & derivados , Ciprofloxacina/uso terapêutico , Terapia Combinada , Pé Diabético/complicações , Pé Diabético/patologia , Combinação de Medicamentos , Humanos , Interferon Tipo I/administração & dosagem , Interferon Tipo I/uso terapêutico , Necrose/etiologia , Necrose/terapia , Tratamento de Ferimentos com Pressão Negativa , Supuração/tratamento farmacológico , Supuração/etiologia , SíndromeRESUMO
Male Zucker diabetic fatty (ZDF) rats were used to study effects of oral administration of interferon tau (IFNT) in reducing obesity. Eighteen ZDF rats (28 days of age) were assigned randomly to receive 0, 4, or 8 µg IFNT/kg body weight (BW) per day (n = 6/group) for 8 weeks. Water consumption was measured every two days. Food intake and BW were recorded weekly. Energy expenditure in 4-, 6-, 8-, and 10-week-old rats was determined using indirect calorimetry. Starting at 7 weeks of age, urinary glucose, and ketone bodies were tested daily. Rates of glucose and oleate oxidation in liver, brown adipose tissue, and abdominal adipose tissue, as well as leucine catabolism in skeletal muscle, and lipolysis in white and brown adipose tissues were greater for rats treated with 8 µg IFNT/kg BW/day in comparison with control rats. Treatment with 8 µg IFNT/kg BW/day increased heat production, reduced BW gain and adiposity, ameliorated fatty liver syndrome, delayed the onset of diabetes, and decreased concentrations of glucose, free fatty acids, triacylglycerol, cholesterol, and branched-chain amino acids in plasma, compared with control rats. Oral administration of 8 µg IFNT/kg BW/day ameliorated oxidative stress in skeletal muscle, liver, and adipose tissue, as indicated by decreased ratios of oxidized glutathione to reduced glutathione and increased concentrations of tetrahydrobiopterin. These results indicate that IFNT stimulates oxidation of energy substrates and reduces obesity in ZDF rats and may have broad important implications for preventing and treating obesity-related diseases in mammals.
Assuntos
Adiposidade/efeitos dos fármacos , Fármacos Antiobesidade/administração & dosagem , Diabetes Mellitus Tipo 2/prevenção & controle , Interferon Tipo I/administração & dosagem , Obesidade/tratamento farmacológico , Proteínas da Gravidez/administração & dosagem , Adiponectina/sangue , Tecido Adiposo Branco/efeitos dos fármacos , Tecido Adiposo Branco/patologia , Administração Oral , Aminoácidos/sangue , Animais , Glicemia , Diabetes Mellitus Tipo 2/sangue , Avaliação Pré-Clínica de Medicamentos , Metabolismo Energético/efeitos dos fármacos , Glicerol/metabolismo , Insulina/sangue , Leptina/sangue , Leucina Transaminase/metabolismo , Lipídeos/sangue , Fígado/efeitos dos fármacos , Fígado/patologia , Masculino , Obesidade/sangue , Obesidade/patologia , Tamanho do Órgão , Oxirredução , Estresse Oxidativo , Ratos , Ratos ZuckerRESUMO
Primary cutaneous B-cell lymphomas (CBCL) represent approximately 20% to 25% of all primary cutaneous lymphomas. With the advent of the World Health Organization-European Organization for Research and Treatment of Cancer (EORTC) Consensus Classification for Cutaneous Lymphomas in 2005, uniform terminology and classification for this rare group of neoplasms were introduced. However, staging procedures and treatment strategies still vary between different cutaneous lymphoma centers, which may be because consensus recommendations for the management of CBCL have never been published. Based on an extensive literature search and discussions within the EORTC Cutaneous Lymphoma Group and the International Society for Cutaneous Lymphomas, the present report aims to provide uniform recommendations for the management of the 3 main groups of CBCL. Because no systematic reviews or (randomized) controlled trials were available, these recommendations are mainly based on retrospective studies and small cohort studies. Despite these limitations, there was consensus among the members of the multidisciplinary expert panel that these recommendations reflect the state-of-the-art management as currently practiced in major cutaneous lymphoma centers. They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL.
Assuntos
Linfoma de Células B/terapia , Neoplasias Cutâneas/terapia , Antibacterianos/uso terapêutico , Anticorpos Monoclonais/administração & dosagem , Anticorpos Monoclonais Murinos , Antineoplásicos/uso terapêutico , Humanos , Interferon Tipo I/administração & dosagem , Doença de Lyme/complicações , Doença de Lyme/tratamento farmacológico , Linfoma de Células B/complicações , Linfoma de Células B/diagnóstico , Linfoma de Células B/patologia , Linfoma de Zona Marginal Tipo Células B/diagnóstico , Linfoma de Zona Marginal Tipo Células B/patologia , Linfoma de Zona Marginal Tipo Células B/terapia , Linfoma Difuso de Grandes Células B/diagnóstico , Linfoma Difuso de Grandes Células B/patologia , Linfoma Difuso de Grandes Células B/terapia , Estadiamento de Neoplasias/métodos , Dosagem Radioterapêutica , Proteínas Recombinantes , Rituximab , Neoplasias Cutâneas/complicações , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/patologiaRESUMO
Recent evidence has suggested that an imbalance between membrane (n-3) and (n-6) fatty acids may contribute to the etiology of autoimmune and neurodegenerative diseases. In this study, the mechanisms by which eicosapentaenoic acid (EPA), gamma-linolenic acid (GLA), and arachidonic acid (AA) modulate neurotransmitters, behavior, and brain inflammation were evaluated in rats that received central saline or interleukin-1beta (IL-1) administrations. In rats treated with saline, only the AA-enriched diet significantly increased anxiety-like behavior in the elevated plus maze, which was associated with increased corticosterone secretion. AA also increased the turnover of dopamine (DA), noradrenaline (NA), and serotonin (5-HT) in the amygdala and increased the prostaglandin (PG)E(2) level in the hippocampus. IL-1 administration slowed rat learning in the water maze and increased anxiety-like behavior, changes which were associated with increased homovanillic acid and 5-HT turnover, decreased NA in the hippocampus and amygdala, decreased DA in the frontal cortex, and decreased IL-10 in limbic brain regions. Increased corticosterone secretion following IL-1 administration was accompanied by increased NA turnover in the hippocampus (P < 0.05) and increased PGE(2) concentration (P < 0.01) in the limbic brain regions. Of the 3 diets tested, only EPA attenuated IL-1-induced behavioral changes (P < 0.05 or 0.01), which was associated with the modulation of EPA on the neuroendocrine and immune changes induced by IL-1. GLA reduced hippocampal PGE(2) concentration in rats given IL-1 (P < 0.01). AA did not counteract any of the changes induced by IL-1. These results suggest that EPA, GLA, and AA play different roles in the neuroendocrine-immune network.
Assuntos
Comportamento Animal/efeitos dos fármacos , Encefalite/induzido quimicamente , Ácidos Graxos Insaturados/administração & dosagem , Interleucina-1beta/administração & dosagem , Neurotransmissores/metabolismo , Tonsila do Cerebelo/química , Animais , Ácido Araquidônico/administração & dosagem , Monoaminas Biogênicas/análise , Monoaminas Biogênicas/metabolismo , Corticosterona/sangue , Dieta , Dinoprostona/análise , Ácido Eicosapentaenoico/administração & dosagem , Lobo Frontal/química , Hipocampo/química , Hipotálamo/química , Interferon Tipo I/administração & dosagem , Interleucina-10/análise , Masculino , Neurotransmissores/análise , Óleo de Palmeira , Óleos de Plantas/administração & dosagem , Ratos , Ratos Wistar , Proteínas Recombinantes , Ácido gama-Linolênico/administração & dosagemRESUMO
In this study, we focused primarily on the antileukemic activity of interferon-beta (IFN-beta) in a murine xenograft model of acute myeloid leukemia (AML). Bolus administration of recombinant IFN-beta via the subcutaneous or intravenous route failed to show efficacy in mice injected with AML cells despite achieving peak plasma IFN-beta levels of more than 200 IU/mL. In contrast, stable expression of IFN-beta following adeno-associated virus (AAV) vector-mediated gene transfer resulted in significant antileukemic activity against primary AML cells derived from patients with poor prognostic markers. An almost linear relationship was observed with stable plasma levels of IFN-beta and antileukemic activity in mice. Even levels below 10 IU/mL were able to reduce tumor load by 50-fold when compared with control animals. These levels of IFN-beta are likely to be nontoxic in humans. Therefore, approaches capable of maintaining stable plasma levels of IFN-beta merit further clinical evaluation in patients with AML.
Assuntos
Interferon beta/administração & dosagem , Interferon beta/farmacologia , Leucemia Mieloide/tratamento farmacológico , Doença Aguda , Adenoviridae/genética , Animais , Relação Dose-Resposta a Droga , Vias de Administração de Medicamentos , Avaliação Pré-Clínica de Medicamentos , Terapia Genética/métodos , Humanos , Interferon Tipo I/administração & dosagem , Interferon Tipo I/farmacologia , Interferon-alfa/administração & dosagem , Interferon-alfa/farmacologia , Camundongos , Transfecção , Transplante Heterólogo , Carga Tumoral/efeitos dos fármacosRESUMO
The data contained in literature and obtained in our own investigations, aimed at the evaluation of the significance of interferon preparations for the correction of immunological disturbances are presented. A special place is given to the role of mild medicinal forms of interferon, the necessity of their use is grounded and good prospects for their inclusion into the complex therapy of infectious diseases are shown.
Assuntos
Antivirais/uso terapêutico , Doenças Transmissíveis/tratamento farmacológico , Interferons/uso terapêutico , Adjuvantes Farmacêuticos , Administração Tópica , Animais , Antivirais/administração & dosagem , Doenças Transmissíveis/imunologia , Enema , Humanos , Injeções , Interferon Tipo I/administração & dosagem , Interferon Tipo I/uso terapêutico , Interferons/administração & dosagem , Proteínas Recombinantes , SupositóriosRESUMO
BACKGROUND: The oral administration of type I interferons (IFNs) have been reported to reduce severity of inflammation in several animal models of autoimmune disease. This study examined whether oral administration of IFN-beta is capable of modulating inflammation in experimental autoimmune uveoretinitis (EAU). METHODS: EAU was induced in rats by immunization with interphotoreceptor retinoid-binding protein (IRBP) emulsified in complete Freund's adjuvant. Rats were treated with either varying doses (10(2), 10(3), 10(4) or 10(5)IU) of mouse recombinant IFN-beta or phosphate-buffered saline for control, via direct oropharyngeal application once a day for 28 days starting 7 days before IRBP immunization. Intraocular inflammation was assessed by slit-lamp biomicroscopy and histopathological examination. Spleen cell proliferation response and cytokine production under IRBP stimulation were assessed. Spleen cell subpopulations were also measured. RESULTS: IFN-beta at doses of either 10(4) or 10(5) IU significantly reduced both the clinical and histopathological severity of EAU. Spleen cell proliferation and IFN-gamma production from rats treated with 10(4) IU IFN-beta were significantly decreased compared with controls. Furthermore, the proportion of both NK cells and NKT cells in the spleen of rats treated with IFN-beta was increased compared with controls. CONCLUSION: These results suggest that the oral administration of IFN-beta reduces inflammation in IRBP-mediated EAU and that the mechanism of this action may involve NK cells and NKT cells.
Assuntos
Doenças Autoimunes/prevenção & controle , Proteínas do Olho , Interferon Tipo I/administração & dosagem , Retinite/prevenção & controle , Uveíte/prevenção & controle , Administração Oral , Animais , Doenças Autoimunes/induzido quimicamente , Doenças Autoimunes/imunologia , Doenças Autoimunes/patologia , Feminino , Citometria de Fluxo , Células Matadoras Naturais/imunologia , Ativação Linfocitária , Ratos , Ratos Endogâmicos Lew , Proteínas Recombinantes , Retinite/induzido quimicamente , Retinite/imunologia , Retinite/patologia , Proteínas de Ligação ao Retinol , Baço/citologia , Linfócitos T/imunologia , Uveíte/induzido quimicamente , Uveíte/imunologia , Uveíte/patologiaRESUMO
Oromucosal (o.m.) administration of interferon-alpha (IFN-alpha) during either allergic sensitization (days 0-6) or the hypersensitive response (days 11 and 12) or both periods caused a dose-dependent reduction in allergen-specific IgE production and allergen-induced eosinophil recruitment in mice sensitized to ragweed pollen, a common allergen in humans. Treatment during the hypersensitive response period alone appeared to be most effective. Oromucosal treatment was as effective as intraperitoneal (i.p.) treatment, with maximum inhibition of both allergen-specific IgE production and allergen-induced eosinophil recruitment observed at a dose of a 1000 IU IFN-alpha. Treatment of animals with up to 10(5) IU murine IFN-alpha/beta (MuIFN-alpha/beta) by either the om. or i.p. route did not inhibit significantly allergen-specific IgG production, which may even have been increased at certain doses of IFN. Treatment of animals with up to 10(5) IU MuIFN-alpha/beta by either the o.m. or i.p. route did not affect significantly total serum IgE or IgG levels. Oromucosal administration of IFN-alpha reduced allergen-specific IgE production and allergen-induced eosinophil recruitment in the absence of detectable toxicity, the induction of H(2) antigen expression, and 2',5'-oligoadenylate synthetase activity associated with parenteral administration of IFN-alpha and thus may find application for the treatment of asthma and associated viral infections.
Assuntos
Alérgenos/imunologia , Hipersensibilidade Imediata/imunologia , Imunização , Interferon Tipo I/administração & dosagem , Pólen/imunologia , 2',5'-Oligoadenilato Sintetase/metabolismo , Administração Intranasal , Alérgenos/administração & dosagem , Animais , Asma/enzimologia , Asma/imunologia , Asma/patologia , Movimento Celular/imunologia , Eosinófilos/imunologia , Eosinófilos/patologia , Epitopos/imunologia , Antígenos de Histocompatibilidade Classe I/biossíntese , Humanos , Hidrocortisona/administração & dosagem , Hipersensibilidade Imediata/enzimologia , Hipersensibilidade Imediata/patologia , Imunoglobulina E/sangue , Imunoglobulina G/sangue , Injeções Intraperitoneais , Interferon Tipo I/uso terapêutico , Interleucina-12/administração & dosagem , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Proteínas RecombinantesRESUMO
Interferons (IFN) have been shown to be effective in protecting animals against lethal viral infections when administered systemically in relatively high doses. Intraperitoneal (i.p.) injection of mice with encephalomyocarditis virus (EMCV) gives rise to a rapidly progressive fatal disease characterized by central nervous system involvement and encephalitis. IFN-alpha has been shown to be effective in protecting mice against lethal EMCV infection when given via parenteral and oral/sublingual routes. The current study was designed to explore the ability of orally/sublingually and intranasally (i.n.) administered IFN-alpha to treat mice infected with EMCV in support of a planned clinical trial to evaluate efficacy of oral IFN-alpha in human viral infections. The primary objective of the study was to determine the efficacy of recombinant murine IFN-alpha (rMuIFN-alpha) in the treatment of mice infected with 100 LD(50) EMCV following oral, i.n., and i.p. administration at doses of 20,000 and 100,000 IU. The results of the current experiment did not indicate protection from infection with EMCV in mice that received IFN by the i.n. or oral/sublingual routes. The negative controls, infection of mice with 100 LD(50) of EMCV followed by treatment with excipient via all three routes, resulted in death of nearly all mice, as expected. The positive control, treatment of EMCV-infected (100 LD(50)) mice with rMuIFN-alpha via the i.p. route, was successful in protecting a significant number of mice from death compared with matched controls. This study points out the need to determine the optimum conditions for administration of oral/sublingual or i.n. IFN to insure maximum efficacy against viral infections.
Assuntos
Antivirais/administração & dosagem , Antivirais/efeitos adversos , Infecções por Cardiovirus/tratamento farmacológico , Vírus da Encefalomiocardite/efeitos dos fármacos , Interferon Tipo I/administração & dosagem , Interferon Tipo I/efeitos adversos , Administração Intranasal , Administração Oral , Animais , Antivirais/uso terapêutico , Infecções por Cardiovirus/mortalidade , Avaliação Pré-Clínica de Medicamentos/métodos , Feminino , Injeções Intraperitoneais , Interferon Tipo I/uso terapêutico , Dose Letal Mediana , Camundongos , Distribuição Aleatória , Proteínas Recombinantes , TitulometriaRESUMO
Many viruses have evolved mechanisms to resist the action of interferon (IFN). These include production of viral gene products that sequester double-stranded RNA (dsRNA) and of small helical RNA. These potentially prevent activation of dsRNA-dependent pathways of IFN action or block expression of cellular genes activated exclusively by dsRNA that may contribute to the antiviral state. Thus, dsRNA might be rate limiting in the development of an IFN-mediated antiviral state. In support of this hypothesis, dsRNA added exogenously to IFN-treated cells in the form of poly(rI):poly(rC) is shown to establish in a dose-dependent manner an antiviral state against two viruses otherwise highly refractory to IFN action, avian reovirus (ARV) and Newcaste disease virus (NDV). Cells exposed singly to high doses of IFN or dsRNA reduced the plaque-forming capacity of these viruses on chicken embryo cells 2-fold. When used in combination, there was up to a 100-fold reduction. In order to abrogate IFN resistance, dsRNA must be added after, not before, an IFN-mediated latent antiviral state is established. dsRNA added exogenously is thought to achieve the threshold required for activation of dsRNA-dependent pathways of IFN action or to induce some dsRNA-stimulated gene whose product acts synergistically with that of some IFN-stimulated gene. The combined sequential treatment with IFN and dsRNA may be useful in overcoming the anti-IFN activity of viruses of clinical interest or in other clinical conditions.
Assuntos
Interferon Tipo I/administração & dosagem , Vírus da Doença de Newcastle/efeitos dos fármacos , Orthoreovirus/efeitos dos fármacos , RNA de Cadeia Dupla/administração & dosagem , Animais , Células Cultivadas , Embrião de Galinha , Relação Dose-Resposta a Droga , Resistência Microbiana a Medicamentos , Sinergismo Farmacológico , Humanos , Indutores de Interferon/administração & dosagem , Vírus da Doença de Newcastle/crescimento & desenvolvimento , Orthoreovirus/crescimento & desenvolvimento , Poli I-C/administração & dosagem , Proteínas Recombinantes , Ensaio de Placa ViralRESUMO
IFN-alphabeta is the only established treatment for viral hepatitis; however, more than 60% of patients are poorly responsive. Because viral hepatitis is associated with inflammation, we hypothesized that inflammation may attenuate the efficacy of IFN therapy. To test this hypothesis, the effect of IL-1beta, one of the major proinflammatory cytokines, on IFN signaling pathway in the liver was examined. Administration of IL-1beta in vivo attenuated IFN-alphabeta-induced STAT1 tyrosine phosphorylation in the liver but not in the spleen. The inhibitory action of IL-1beta in vivo was not affected by depleting hepatic Kupffer cells, suggesting that IL-1beta may directly target IFN-alphabeta signaling in hepatocytes. Indeed, pretreatment of human hepatocellular carcinoma HepG2 cells with IL-1beta suppressed IFN-alphabeta-induced antiviral activity and antiviral protein MxA mRNA expression. Furthermore, IL-1beta attenuated IFN-alphabeta-induced STAT1 binding and tyrosine phosphorylation without affecting the level of STAT1 protein. This inhibitory effect can be reversed by pretreatment with either proteasome inhibitors or transfection of dominant negative NF-kappaB inducing kinase mutants. Taken together, these findings suggest that IL-1beta attenuates IFN-alphabeta-induced STAT1 activation by a proteasome-dependent mechanism. In view of high levels of IL-1beta in the serum or within the liver of patients with chronic liver diseases, attenuation of IFN-alphabeta signaling in the liver by IL-1beta could be one of the mechanisms underlying the resistance to IFN therapy in chronic hepatitis C, and IL-1beta could be a potential therapeutic target for improving the efficacy of IFN therapy.
Assuntos
Adjuvantes Imunológicos/fisiologia , Antivirais/biossíntese , Cisteína Endopeptidases/fisiologia , Proteínas de Ligação a DNA/metabolismo , Interferon Tipo I/farmacologia , Interleucina-1/fisiologia , Fígado/imunologia , Fígado/virologia , Complexos Multienzimáticos/fisiologia , Transativadores/metabolismo , Animais , Antivirais/antagonistas & inibidores , Ligação Competitiva/imunologia , Carcinoma Hepatocelular/imunologia , Carcinoma Hepatocelular/virologia , Proteínas de Ligação a DNA/antagonistas & inibidores , Proteínas de Ligação a DNA/biossíntese , Ativação Enzimática/imunologia , Feminino , Humanos , Imunossupressores/farmacologia , Injeções Intravenosas , Interferon Tipo I/administração & dosagem , Interferon Tipo I/antagonistas & inibidores , Interferon-alfa/antagonistas & inibidores , Interferon-alfa/farmacologia , Janus Quinase 1 , Células de Kupffer/imunologia , Células de Kupffer/metabolismo , Fígado/enzimologia , Fígado/metabolismo , Camundongos , Camundongos Endogâmicos ICR , Fosforilação , Complexo de Endopeptidases do Proteassoma , Biossíntese de Proteínas , Proteínas Tirosina Quinases/metabolismo , Proteínas/metabolismo , Proteínas/fisiologia , Ratos , Fator de Transcrição STAT1 , Transdução de Sinais/imunologia , Baço/imunologia , Baço/metabolismo , TYK2 Quinase , Transativadores/antagonistas & inibidores , Transativadores/biossíntese , Células Tumorais Cultivadas , Tirosina/metabolismoRESUMO
The effect of a single intracerebroventricular (i.c.v.) injection of alpha-IFN on levels of central monoamines and their metabolites in six brain regions (frontal cortex, striatum, hypothalamus, hippocampus, mid brain and medulla) of the rat was investigated. Wistar rats (n=10) were decapitated 2 h after i.c.v. injection of alpha-IFN. The brain tissues were homogenized, and monoamine concentrations were measured by high-performance liquid chromatography with an electrochemical detector. The levels of 5-hydroxytryptamine (5-HT) were significantly reduced in the frontal cortex in a dose-dependent manner, and the levels of both 5-HT and 5-hydroxyindoleacetic acid (5-HIAA) were reduced in the mid brain and the striatum. The levels of noradrenaline (NA) were also significantly reduced in a dose-dependent manner in the frontal cortex. Some neurophysiological changes that affect activity of the noradrenergic or/and the serotonergic neuron system may occur during IFN therapy.
Assuntos
Encéfalo/metabolismo , Catecolaminas/metabolismo , Interferon Tipo I/farmacologia , Serotonina/metabolismo , Ácido 3,4-Di-Hidroxifenilacético/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Ventrículos Cerebrais/efeitos dos fármacos , Ventrículos Cerebrais/fisiologia , Corpo Estriado/metabolismo , Dopamina/metabolismo , Lobo Frontal/metabolismo , Hipocampo/metabolismo , Ácido Homovanílico/metabolismo , Ácido Hidroxi-Indolacético/metabolismo , Hipotálamo/metabolismo , Injeções Intraventriculares , Interferon Tipo I/administração & dosagem , Masculino , Bulbo/metabolismo , Mesencéfalo/metabolismo , Norepinefrina/metabolismo , Ratos , Ratos Wistar , Proteínas RecombinantesRESUMO
Using the tail-flick induced by electro-stimulation as a pain marker, it was found that pain threshold (PT) was significantly increased after injecting interferon-alpha (IFN alpha) into the lateral ventricle of rats. This effect was dosage-dependent and abolished by monoclonal antibody (McAb) to IFN alpha. Naloxone could inhibit the analgesic effect of IFN alpha, suggesting that the analgesic effect of IFN alpha be related to the opioid receptors. Beta-funaltrexamine (beta-FNA), the mu specific receptor antagonist could completely block the analgesic effect of IFN alpha. The selective delta-opioid receptor antagonist, ICI174,864 and the kappa-opioid receptor antagonist, nor-BNI both failed to prevent the analgesic effect of IFN alpha. IFN alpha could significantly inhibit the production of the cAMP stimulated by forskolin in SK-N-SH cells expressing the mu-opioid receptor, not in NG108-15 cells expressing the delta-opioid receptor uniformly. The results obtained provide further evidence for opioid activity of IFN alpha and suggest that this effect is mediated by central opioid receptors of the mu subtype. The evidence is consistent with the hypothesis that multiple actions of cytokines, such as immunoregulatory and neuroregulatory effects, might be mediated by distinct domains of cytokines interacting with different receptors.
Assuntos
Analgesia , Interferon Tipo I/farmacologia , Receptores Opioides mu/fisiologia , Animais , Anticorpos Monoclonais/farmacologia , Linhagem Celular , Relação Dose-Resposta a Droga , Estimulação Elétrica , Encefalina Leucina/análogos & derivados , Encefalina Leucina/farmacologia , Injeções Intraventriculares , Interferon Tipo I/administração & dosagem , Interferon Tipo I/antagonistas & inibidores , Masculino , Naloxona/farmacologia , Naltrexona/análogos & derivados , Naltrexona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Medição da Dor , Ratos , Ratos Sprague-Dawley , Proteínas RecombinantesRESUMO
Interferon alpha (IFN alpha) has been demonstrated to possess a significant biological activity for cutaneous malignant melanoma (CMM). Although multiple adjuvant trials utilizing IFNá have been tested, no consensus on the optimal dosing schedule has been reached. From February 1993 to October 1997 we enrolled 86 CMM patients using low doses of IFN alpha-2b (3 MU/d TIW SC for 3 years) in a phase II study. Our present data show a median disease-free survival (DFS) of 30 months (range 2-62), comparable to those obtained in high-dose IFN alpha trials. These findings suggest that positive results may be also obtained using low doses of IFN alpha in adjuvant treatment of CMM patients. in contrast to the high dose, the low dose regimen was well tolerated with an acceptable quality of life of patients.
Assuntos
Interferon Tipo I/uso terapêutico , Melanoma/tratamento farmacológico , Pele/patologia , Quimioterapia Adjuvante , Intervalo Livre de Doença , Feminino , Humanos , Interferon Tipo I/administração & dosagem , Interferon Tipo I/efeitos adversos , Itália , Masculino , Melanoma/mortalidade , Melanoma/patologia , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Qualidade de Vida , Proteínas Recombinantes , Fatores de TempoRESUMO
AIDS: New treatment options for chronic hepatitis C (HCV) infection are examined. Studies show the efficacy of interferon alfa-2b in normalization of serum alanine aminotransferase and histological improvement in necroinflammatory liver disease. However, 70 to 80 percent experiencing normalization usually relapse within 1 year after treatment. Ten to 20 percent will have a sustained response lasting at least 3 years. Ideas for improving treatment response include longer initial treatment regimens, increasing dosages of interferon alpha, or adding another agent to interferon alpha. Based on encouraging study results, the interferon/ribavirin combination has been approved by the Food and Drug Administration (FDA) in HCV patients relapsing following interferon alpha monotherapy. So far the FDA has approved interferon alfa-2b, interferon alfa-2a, alfacon-1, and interferon alfa-2b/ribavirin as treatments for HCV; ribavirin alone is not effective against HCV infection. Other drugs are being tested with interferon alpha but have not generated enough substantive data. Thymosin, an immune modulator that enhances the body's production of interferon and interleukin rather than attacking HCV directly, is also being investigated. Oral dosing of interferon is in clinical trials for hepatitis B, and the results may be applicable to HCV. Alternative therapies are gaining wider interest such as using milk thistle for liver regeneration or using licorice root for quelling liver inflammation. As for transmission risk, there is little evidence supporting sexual activity as a major risk factor, however, some risk is reported with anal intercourse, sex during the menstrual cycles, and years of cohabitation with an infected partner.^ieng
Assuntos
Antivirais/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Interferon Tipo I/uso terapêutico , Ribavirina/uso terapêutico , Antivirais/administração & dosagem , Ensaios Clínicos como Assunto , Quimioterapia Combinada , Genótipo , Hepacivirus/genética , Hepacivirus/isolamento & purificação , Hepatite C/transmissão , Humanos , Interferon Tipo I/administração & dosagem , RNA Viral/sangue , Proteínas Recombinantes , Ribavirina/administração & dosagem , Resultado do Tratamento , Carga ViralRESUMO
Interferon tau (IFN tau) is the conceptus-produced antiluteolytic signal in ruminants. Three experiments examined the effects of s.c. administration of recombinant ovine (ro)IFN tau on interestrous interval (IEI), oxytocin (OT)-induced uterine prostaglandin F2alpha metabolite (PGFM) production, rectal temperature (RT), respiration rate (RR), and plasma concentrations of progesterone, cortisol, LH, and antiviral activity (AVA) in plasma and uterine flushings. In experiment I, 20 ewes were treated s.c. with either 0, 1, 2, or 4 mg/day roIFN tau (0.7 x 10(8) U/mg; 5 ewes/dosage) from Days 11 to 15 of the estrous cycle (estrus = Day 0) and were challenged with OT (30 IU) on Day 15. Jugular blood samples were collected at -10, 0, 10, 20, 30, 40, 50, and 60 min relative to the OT challenge and assayed for PGFM. Recombinant oIFN tau increased IEI (16.7, 18.7, and 22.6 +/- 0.6 days for 0, 2, and 4 mg roIFN tau, respectively, p < 0.01). Recombinant oIFN tau did not affect peak PGFM response to OT (2309 +/- 172 pg/ml; p > 0.1). However, the 4 mg/day dosage delayed the time to peak PGFM (32.4 vs. 47.5 +/- 3.4 min; p < 0.01, 0 vs. 4 mg) and resulted in approximately 200% higher concentrations of PGFM at 60 min post-OT (0 vs. 4 mg/day, p < 0.07). Experiment II was similar to experiment I, except that only the 0- and 4-mg/day dosages of roIFN tau were administered. Ewes were hysterectomized on Day 16, and assay of uterine flushes detected no AVA from ewes treated with either 0 or 4 mg/day roIFN tau. In experiment III, 20 ewes were treated s.c. with either 0, 2, 4, or 6 mg roIFN tau on Day 12. Blood samples, RT, and RR were obtained at frequent intervals for 24 h, and plasma was assayed for progesterone, cortisol, LH, and AVA. Plasma AVA, which increased in a dose-dependent manner, was detectable within 60 min and remained elevated at 24 h compared to control values. RT (elevated 0.5-1.0 degrees C), RR, and cortisol increased in response to all dosages of roIFN tau, with peak values occurring 150-180 min postinjection. For all dosages of roIFN tau, plasma progesterone declined from 120 to 360 min posttreatment and then returned to pretreatment values by 24 h (p < 0.01) as compared to controls. Overall, exogenous roIFN tau altered uterine PGFM response to OT from a pulse to a gradual and sustained elevation and extended IEI with only a transient decline in progesterone and mild hyperthermia, effects that are not expected to compromise pregnancy.
Assuntos
Estro/efeitos dos fármacos , Hormônios/sangue , Interferon Tipo I/farmacologia , Proteínas da Gravidez/farmacologia , Útero/efeitos dos fármacos , Animais , Antivirais/sangue , Temperatura Corporal/efeitos dos fármacos , Dinoprosta/metabolismo , Avaliação Pré-Clínica de Medicamentos , Feminino , Fertilidade/efeitos dos fármacos , Hidrocortisona/sangue , Interferon Tipo I/administração & dosagem , Interferon Tipo I/toxicidade , Hormônio Luteinizante/sangue , Ocitocina/farmacologia , Gravidez , Proteínas da Gravidez/administração & dosagem , Proteínas da Gravidez/toxicidade , Progesterona/sangue , Proteínas Recombinantes/administração & dosagem , Proteínas Recombinantes/farmacologia , Proteínas Recombinantes/toxicidade , Ovinos , Útero/metabolismoRESUMO
Although ethanol injection in combination with microwaval hyperthermia and systemic administration of interleukin-2 was found to be very effective in suppressing the growth of B16 melanoma nodules with a size of less than 7 mm in diameter in our previous experiments, the growth of B16 melanomas with a size of greater than 10 mm in diameter was very difficult to control with any of the therapeutic modalities examined. In subsequent experiments, we investigated whether ethanol injection (150 microliters/injection) in combination with local injection of beta-interferon (2 x 10(4) IU/injection) and local microwaval hyperthermia at 43 degrees C for 15 min was able to suppress the growth of melanoma nodules and to prolong survival times of melanoma-burdened mice. The results were that we successfully suppressed the growth of melanoma nodules of that size for the first time with combinations of the therapeutic modalities described above. Infiltration of immunocompetent cells such as T lymphocytes and NK cells was clearly observed in the melanoma tissues treated with the therapeutic combination. These experimental results should be applied to the treatment of human melanomas in advanced stages which have no indications for surgical operation.
Assuntos
Etanol/administração & dosagem , Hipertermia Induzida/métodos , Interferon Tipo I/administração & dosagem , Interferon beta/administração & dosagem , Melanoma Experimental/terapia , Animais , Terapia Combinada , Esquema de Medicação , Humanos , Injeções Intralesionais , Células Matadoras Naturais/imunologia , Células Matadoras Naturais/patologia , Linfócitos do Interstício Tumoral/imunologia , Linfócitos do Interstício Tumoral/patologia , Melanoma Experimental/imunologia , Melanoma Experimental/patologia , Camundongos , Camundongos Endogâmicos C57BL , Micro-Ondas/uso terapêutico , Proteínas Recombinantes , Fatores de TempoRESUMO
We have investigated the effects of interferon-alpha (IFN-alpha) and 5-fluorouracil (5-FU) on meningioma cells in two different culture systems, evaluated by the uptake of radiolabelled methionine. With both IFN-alpha and 5-FU an inhibitory effect on the uptake of radiolabelled methionine by the meningioma cells was demonstrated, and we found a synergistic inhibitory effect with a combination of IFN-alpha and 5-FU. To obtain a maximal inhibition of cell metabolism without causing cell toxicity, we were able to decrease the dose of 5-FU by simultaneously adding IFN-alpha. Our results suggest that a combined treatment of IFN-alpha and 5-FU may be a successful alternative for patients with inoperable meningiomas. A novel in vitro positron emission tomography technique was used for the study of metabolic changes in tumour cells caused by drug treatment, which is complementary to conventional cell culture techniques.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Neoplasias Meníngeas/tratamento farmacológico , Meningioma/tratamento farmacológico , Adulto , Radioisótopos de Carbono , Divisão Celular/efeitos dos fármacos , Sinergismo Farmacológico , Feminino , Fluoruracila/administração & dosagem , Humanos , Interferon Tipo I/administração & dosagem , Masculino , Neoplasias Meníngeas/metabolismo , Meningioma/metabolismo , Metionina/farmacocinética , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/tratamento farmacológico , Proteínas Recombinantes , Células Tumorais CultivadasRESUMO
The purpose of this study was to determine the maximum tolerated dose and dose-limiting toxicities of 5-fluorouracil (5-FU) when administered concurrently with recombinant IFN-alpha using four continuous infusion (CI) dosing schedules of 5-FU. Forty-five patients with advanced or refractory cancers were treated with 5-FU by CI, plus IFN during the infusion only, by one of four schedules: schedule A: 24-h 5-FU infusion repeated weekly, 9 x 10(6) units IFN x 2 doses weekly; schedule B: 48-h 5-FU infusion repeated weekly, 9 x 10(6) units IFN x 4 doses weekly; schedule C: 5-day 5-FU infusion repeated every 3 weeks, 9 x 10(6) units IFN three times weekly; and schedule D: 21-day 5-FU infusion, repeated after 7 days off therapy, 9 x 10(6) units IFN three times weekly. At least three patients were treated at all dose levels. Doses of 5-FU were escalated to the next level if less than one half of the patients at a given level developed grades 2-4 toxicity. The maximum tolerated dose for 5-FU was 2150 mg/m2/week for schedule A (24-h CI), 2350 mg/m2/week for schedule B (48-h CI), 750 mg/m2/day for schedule C (5-day CI), and 175 mg/m2/day for schedule D (21-day CI). Median delivered dose intensities at these levels were 1788 mg/m2/week for schedule A, 2192 mg/m2/week for schedule B, 1250 mg/m2/week for schedule C, and 593 mg/m2/week for schedule D. The dose-limiting toxicities were hematological and gastrointestinal (stomatitis, diarrhea, nausea, anorexia) for schedules A and B and gastrointestinal (mostly stomatitis) for schedules C and D. Severe fatigue due to IFN was rare. Responses correlated with toxicity >/= grade 2, but not with increased dose intensity. Responses were noted in several tumor types on schedules A, B, and D. 5-FU can be combined with IFN using 24- and 48-h high-dose and long-term low-dose CI schedules, with large differences in dose intensity at maximum tolerated dose. Shorter infusions produce less mucosal and more hematological toxicity. Tumor responses were seen on both short- and long-term CI schedules. Future studies can establish the efficacies of these new schedules of 5-FU/IFN administration in specific tumor types.
Assuntos
Fluoruracila/efeitos adversos , Interferon Tipo I/efeitos adversos , Neoplasias/terapia , Adulto , Idoso , Idoso de 80 Anos ou mais , Terapia Combinada , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Fluoruracila/administração & dosagem , Humanos , Infusões Intravenosas , Interferon Tipo I/administração & dosagem , Masculino , Pessoa de Meia-Idade , Proteínas RecombinantesRESUMO
A pilot study was performed to assess the feasibility of combining 5-fluorouracil, recombinant alpha-2b-interferon, external radiation therapy and intraluminal high dose rate brachytherapy with surgery in patients with locally advanced esophageal carcinoma. 5-fluorouracil, 750 mg m-2, was administered via continuous 5-day infusion beginning day 1 and weekly thereafter; interferon, 10 mu subcutaneously, was administered three times per week beginning day 1 and sargramostin, 5 micrograms kg-1, was administered on days without 5-fluorouracil. External radiation began on day one using 1.5 daily fractions to 55.5 Gy. Intraluminal brachytherapy was delivered concomitantly once each week for 5 fractions of 4 Gy. None of the first eight patients went to surgery. The external radiation was changed to 1.5 Gy BID to 45 Gy followed by BID intraluminal radiation to 15 Gy. Of the last four patients, there was one case of radiation myelitis. It was found that successful surgery was not possible and excessive toxicities, including radiation myelitis, occurred with this aggressive regimen.